Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506)

Annals of Neurology

Volumn 40, Issue 4, 1996, Pages 575-580

  Small, Steven L ^a   Fukui, Melanie B ^a   Bramblett, Gregory T ^a   Eidelman, Benjamin H ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADULT; ARTICLE; BRAIN BIOPSY; CASE REPORT; DEMYELINATION; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOENCEPHALOPATHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN TRANSPLANTATION; PRIORITY JOURNAL;

ADULT; BLINDNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCCIPITAL LOBE; PARIETAL LOBE; REMISSION, SPONTANEOUS; TACROLIMUS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0029859123     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410400406     Document Type: Article

References (20)

1. Tacrolimus (FK506) for organ transplants. Med Lett 1994:82-83
2. Porayko MK, Wiesner RH, Group USMFS. US multicenter prospective randomized trial comparing primary immunosuppression with FK506 vs cyclosporin (CyA) following liver transplantation. Gastroenterology 1994;104:A974 (Abstract)
3. European FK506 Multicentre Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-428
4. Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurologic complications of FK506. Transplant Proc 1991;23:3175-3178
5. Reyes J, Gayowski T, Fung J, et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. Transplantation 1990;50:1043-1045
6. Wijdicks EFM, Weisner RH, Dahlke RN, et al. FK506-induced neurotoxicity in liver transplantation. Ann Neurol 1994;35:498-501
7. Shutter LA, Green JP, Newman NJ, et al. Cortical blindness and white matter lesions in a patient receiving FK506 after liver transplantation. Neurology 1993;43:2417-2418
8. Berden JHM, Hoitsma AJ, Merx JL, et al. Severe central nervous system toxicity associated with cyclosporin. Lancet 1985;1:219-220 (Letter)
9. Palmer BF, Toto RD. Severe neurologic toxicity induced by cyclosporin A in three renal transplant patients. Am J Kidney Dis 1991;XVIII:116-121
10. de Groen PC, Aksamit AJ, Rakela J, et al. Central nervous system toxicity after liver transplantation. N Engl J Med 1987;317:861-866
11. Boon AP, Adams DH, Carey MP, et al. Cyclosporine associated cerebral lesions in liver transplantation. Lancet 1988;1:1457
12. Hughes RL. Cyclosporin-related central nervous system toxicity in cardiac transplantation. N Engl J Med 1990:323:420-421
13. Rubin AM, Kang H. Cerebral blindness and encephalopathy with cyclosporin toxicity. Neurology 1987:37:1072-1076
14. Cilio MR, Danhaive O, Gadisseux JF, et al. Unusual cyclosporin related neurological complications in recipients of liver transplants. Arch Dis Child 1993:68:405-407
15. Truwit CL, Denaro CP, Lake JR, et al. MR imaging of reversible cyclosporin A-induced neurotoxicity. Am J Neuroradiol 1991:12:651-659
16. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500
17. Friese CE, Rowley H, Lake J, et al. Similar clinical presentation of neurotoxicity following FK506 and cyclosporin in a liver transplant recipient. Transplant Proc 1991;23:3173-3174
18. Cameron AM, Steinet JP, Sabatini DM, et al. lmmunophilin FK506 binding protein associated with inositol 1,4,5-triphosphate receptor modulates calcium flux. Proc Natl Acad Sci USA 1995;92:1784-1788
19. Liu J. FK-506 and cyclosporin: molecular probes for studying intracellular signal transduction. Trends Pharm Sci 1993;14:182-188
20. Dumont FJ, Staruch MJ, Koprak SL, et al. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 1992;176:751-760